Severe Irritant Contact Dermatitis Causing Skin Ulceration Secondary to a Testosterone Patch

by Nathan Lawrentschuk, Neil Fleshner
Published 2009-01-01

Population‐based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non‐metastatic muscle‐invasive bla...

by Tarik Benidir, Jaime Herrera‐Caceres, Christopher Wallis, Katherine Lajkosz, Neil Fleshner
Published 2021-04-01

A whole-genome SNP association study of NCI60 cell line panel indicates a role of Ca2+ signaling in selenium resistance.

by Sevtap Savas, Laurent Briollais, Irada Ibrahim-zada, Hamdi Jarjanazi, Yun Hee Choi, Mireia Musquera, Neil Fleshner, Vasundara Venkateswaran, Hilmi Ozcelik
Published 2010-01-01

Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer

by Ameya D Puranik, Clarisse Dromain, Neil Fleshner, Mike Sathekge, Marianne Pavel, Nina Eberhardt, Friedemann Zengerling, Ralf Marienfeld, Michael Grunert, Vikas Prasad
Published 2021-07-01

Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays.

by Ken Kron, Vaijayanti Pethe, Laurent Briollais, Bekim Sadikovic, Hilmi Ozcelik, Alia Sunderji, Vasundara Venkateswaran, Jehonathan Pinthus, Neil Fleshner, Theodorus van der Kwast, Bharati Bapat
Published 2009-01-01

Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes

by Yazan Qaoud, Piero Bettoli, Noelia Sanmamed-Salgado, Jaime O. Herrera-Caceres, Mohamad Baker Berjaoui, Katherine Lajkosz, Hanan Goldberg, Dixon T.S. Woon, Zoe Glase, Sangeet Ghai, Antonio Finelli, Peter Chung, Nathan Perlis, Neil Fleshner, Alejandro Berlin
Published 2020-10-01

Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille...

by Sultan S Alkhateeb, Mischel Neill, Sas Bar-Moshe, Bas Van Rhijn, David M Kakiashvili, Neil Fleshner, Michael Jewett, Michel Petein, Claude Schulman, Sally Hanna, Peter J Bostrom, Thierry Roumeguere, Shahrokh F Shariat, Sandrine Rorive, Alexandre R Zlotta
Published 2011-01-01

A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer

by Fang Zhao, Ekaterina Olkhov-Mitsel, Shivani Kamdar, Renu Jeyapala, Julia Garcia, Rachel Hurst, Marcelino Yazbek Hanna, Robert Mills, Alexandra V. Tuzova, Eve O’Reilly, Sarah Kelly, Colin Cooper, The Movember Urine Biomarker Consortium, Daniel Brewer, Antoinette S. Perry, Jeremy Clark, Neil Fleshner, Bharati Bapat
Published 2018-11-01

Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network...

by Andrée-Anne Grosset, Véronique Ouellet, Christine Caron, Gabriela Fragoso, Véronique Barrès, Nathalie Delvoye, Mathieu Latour, Armen Aprikian, Alain Bergeron, Simone Chevalier, Ladan Fazli, Neil Fleshner, Martin Gleave, Pierre Karakiewicz, Louis Lacombe, Jean-Baptiste Lattouf, Theodorus van der Kwast, Dominique Trudel, Anne-Marie Mes-Masson, Fred Saad, Canadian Prostate Cancer Biomarker Network
Published 2019-07-01

Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

by Michael A. Kiebish, Poornima Tekumalla, Shobha Ravipaty, Albert Dobi, Shiv Srivastava, Wenfang Wu, Saurabh Patil, Tracey Friss, Allison Klotz, Alagarsamy Srinivasan, Jennifer Cullen, Inger L. Rosner, Amina Ali, Sandra Laszlo, Michele Petrovic, Neil Fleshner, Jeonifer Garren, Greg Miller, Nischal Mahaveer Chand, Leonardo O. Rodrigues, Elder Granger, Mark D. Kellogg, Shen Luan, Eleftherios Diamandis, Viatcheslav R. Akmaev, Rangaprasad Sarangarajan, Chas Bountra, Stephen J. Freedland, David G. McLeod, Niven R. Narain
Published 2021-07-01